Literature DB >> 19347007

Transplantation: Steroid use in HCV-infected liver transplant recipients.

Bruno Roche, Didier Samuel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19347007     DOI： 10.1038/nrgastro.2009.38

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  9 in total

1.  Immunosuppression and outcomes of patients transplanted for hepatitis C.

Authors:  John R Lake
Journal:  J Hepatol       Date:  2006-02-17       Impact factor: 25.083

2.  The association between hepatitis C infection and survival after orthotopic liver transplantation.

Authors:  Lisa M Forman; James D Lewis; Jesse A Berlin; Harold I Feldman; Michael R Lucey
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

3.  Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis.

Authors:  Marina Berenguer; Ana Royuela; Javier Zamora
Journal:  Liver Transpl       Date:  2007-01       Impact factor: 5.799

4.  Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials.

Authors:  Dorry L Segev; Stephen M Sozio; Eun Ji Shin; Susanna M Nazarian; Hari Nathan; Paul J Thuluvath; Robert A Montgomery; Andrew M Cameron; Warren R Maley
Journal:  Liver Transpl       Date:  2008-04       Impact factor: 5.799

Review 5.  Risk factors for hepatitis C recurrence after liver transplantation.

Authors:  B Roche; D Samuel
Journal:  J Viral Hepat       Date:  2007-11       Impact factor: 3.728

6.  Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.

Authors:  Marina Berenguer; Victoria Aguilera; Martín Prieto; Fernando San Juan; José M Rayón; Salvador Benlloch; Joaquín Berenguer
Journal:  J Hepatol       Date:  2006-02-06       Impact factor: 25.083

7.  Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study.

Authors:  Goran B G Klintmalm; W Kenneth Washburn; Steven M Rudich; Thomas G Heffron; Lewis W Teperman; Carlos Fasola; Devin E Eckhoff; George J Netto; Eliezer Katz
Journal:  Liver Transpl       Date:  2007-11       Impact factor: 5.799

Review 8.  Minimization of steroids in liver transplantation.

Authors:  Jan Lerut; Eliano Bonaccorsi-Riani; Patrice Finet; Pierre Gianello
Journal:  Transpl Int       Date:  2009-01       Impact factor: 3.782

9.  Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study.

Authors:  Laura Lladó; Joan Fabregat; Jose Castellote; Emilio Ramos; Xavier Xiol; Jaume Torras; Teresa Serrano; Carme Baliellas; Joan Figueras; Agustin Garcia-Gil; Antoni Rafecas
Journal:  Liver Transpl       Date:  2008-12       Impact factor: 5.799
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.